Peptide industry stats
Active trial counts come from ClinicalTrials.gov. The PCAC column shows where each peptide we track stands with the FDA's Pharmacy Compounding Advisory Committee.
Last updated: 1 November 2026
- Compounds tracked
- 23
- Active trials
- 26
- Recommended at July 2026 PCAC
- 6
One was not recommended (DSIP). FDA final action is pending.
- Awaiting February 2027 PCAC
- 3
Counts only the compounds we track.
Injectable and non-injectable GHK-Cu moved in opposite Category 1/2 directions; both forms are slated for the Feb 2027 consultation. See content/_meta/pcac-2026-docket.md for the route split.
Active-trial counts come from live ClinicalTrials.gov queries, filtered to trials recruiting, not yet recruiting, or active but not recruiting, refreshed monthly. PCAC status comes from FDA's meeting notices and published reports of the votes. FDA has not yet posted its official record of the July 2026 votes. PCAC only advises. FDA final action on the July 2026 recommendations is pending.